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Abstract 
This study examined whether placebo responses were predicted by a theoretical model of 
specific and general treatment beliefs. Using a randomised cross-over, experimental design 
(168 healthy individuals) we assessed whether responses to a cold pressor task were 
influenced by two placebo creams described as Pharmaceutical vs Natural origin. We 
assessed whether placebo responses were predicted by pre-treatment beliefs about the 
treatments (placebo) and by beliefs about the pain. The efficacy of both Pharmaceutical and 
Natural Placebos in reducing Pain Intensity was predicted by aspects of pain catastrophizing 
including Feelings of Helplessness (Pharmaceutical: B=0.03, p<0.01, Natural: B=0.02, 
p<0.05) and Magnification of Pain (Pharmaceutical: B=0.04, p<0.05, Natural: B=0.05, 
p<0.05) but also by pre-treatment Necessity beliefs (Pharmaceutical: B=0.21, p<0.01, 
Natural: B=0.16, p<0.05) and, for the Pharmaceutical condition, by more general beliefs in 
personal sensitivity to pharmaceuticals (B=0.14, p<0.05). Treatment Necessity beliefs also 
partially mediated the effects of Helplessness on placebo responses. Treatment Necessity 
beliefs for the Pharmaceutical Placebo were influenced by general pharmaceutical beliefs 
whereas Necessity beliefs for the Natural Placebo were informed by general background 
beliefs about holistic treatments. Our findings demonstrate that treatment beliefs influence 
the placebo effect suggesting that they may offer an additional approach for understanding 
the placebo effect. 
Perspective: Placebo effects contribute to responses to active analgesics. Understanding 
how beliefs about different types of medicines influence placebo analgesia may be useful in 
understanding variations in treatment response. Using the cold-pressor paradigm we found 
that placebo analgesia is influenced by beliefs about natural remedies, pharmaceutical 
medicines and about pain. 
Key words: 
• Treatment beliefs 
• Placebo effect 
• Pharmaceutical medicines 
• Natural remedies 
• Analgesia 
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1. Introduction 
Placebo effects are thought to be influenced by beliefs. These are usually operationalised as 
treatment expectations but are other beliefs also important? Horne and colleagues have 
developed a theoretical model for the origin and effects of beliefs about pharmaceuticals 
[14]. The model differentiates between specific and general beliefs. Specific beliefs pertain to 
a particular medicine and are often operationalised as how the individual judges their 
personal need for the treatment (necessity beliefs), relative to their concerns about potential 
harms [15; 16]. 
Specific treatment evaluations are related to more general ‘background’ beliefs or  
pharmaceutical schema comprising ideas about medicines as objects (e.g. the degree to 
which they are generally harmful, beneficial, overused by doctors etc. [20]) and beliefs about 
self in relation to medicines (e.g. beliefs about personal sensitivity to medicines [17]). In 
representations of pharmaceuticals, their harm is often linked to their essence as 
manufactured ‘chemicals’, in contrast to ‘natural’ remedies that are perceived more positively 
[14]. Negative pharmaceutical schemas are often associated with more positive beliefs about 
natural remedies [9; 14].   
The anticipated relationship between specific and general beliefs about treatment can be 
represented by the theoretical model shown in Figure 1. This model is derived from 
observations that specific treatment beliefs such as treatment necessity  are influenced by 
more general background beliefs about treatment i.e. pharmaceutical schema [7; 19], but 
also by representations of the condition being treated [22]. In situations where treatment is 
prescribed to reduce pain, treatment necessity beliefs are likely to be related to perceptions 
of the pain (e.g. pain severity ratings) and to related cognitions such as pain catastrophizing 
(see Figure 1) [34; 36]. 
Figure 1: Hypothesised relationship between beliefs about pain, general treatment beliefs, 
treatment necessity and the placebo effect. 
In this study we examine whether our model of treatment representations can explain 
variations in the placebo effect. To do this we prepared two (deceptive) placebo creams that 
were differentially described as having pharmaceutical vs a natural origin. This enabled us to 
examine whether responses to the placebo (e.g. reduction in pain scores) were related to 
specific beliefs and general beliefs about the treatments. 
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We will test the following hypotheses:  
Hypothesis 1: Variation in placebo responses in both conditions will be predicted by the 
participant’s Specific Necessity beliefs (i.e. their perception of personal need for the specific 
‘treatment’ pharmaceutical vs. natural. 
Hypothesis 2: High pain catastrophizing will be associated with stronger Necessity beliefs 
and a larger placebo effect. 
Hypothesis 3: Specific Necessity will be differentially influenced by general pharmaceutical 
schema and general beliefs about complimentary medicine. More positive pharmaceutical 
schema will be associated with stronger beliefs in the necessity for the Pharmaceutical 
Placebo and more positive beliefs in complementary and natural medicine with stronger 
beliefs in the necessity for the Natural Placebo. 
Hypothesis 4: Negative pharmaceutical schema will be associated with more positive beliefs 
about complementary and natural remedies and preferences for this type of treatment. 
2. Method 
This study was approved by the UCL Ethics Committee (ref: 4875/002). The study had a 
within-subject crossover design. Participants attended a single testing session in which they 
completed 3 conditions in a random order: Pharmaceutical Condition, Natural Condition and 
No Placebo Condition. 
2.1. Sample and recruitment procedure 
The sample size was calculated using G Power (G*Power v3.1.9.2), for testing a linear 
multiple regression model (fixed, R2 increase), 80% power and an alpha error probability of 
0.05. We calculated the required sample size based on a study which reported that 
expectations explained 7.3% of the variance in cold pressor pain severity [35]. A sample size 
of 168 was required in order to explain a total variance of 7.3% by 5 predictor variables of 
interest (Necessity, Concerns, General Benefit, General Harm and PSM) in a multiple 
regression model. 
Participants were invited to take part in a study comparing the effectiveness of two new pain-
relieving creams via the UCL Announcement Email Service between June and December 
2014. Participants were included if aged 18 years and above, and able to sufficiently 
understand spoken and written English. Participants were excluded if they reported a history 
of the following medical conditions: fainting/seizures, cardiovascular disease, circulation 
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disorders, or if they had the following conditions in the past two weeks: chronic pain, back 
pain, severe headaches, and arthritis or hand injuries. Participants were also excluded if 
they were currently taking medication for pain, anti-depressants or sedatives. Potential 
participants were emailed the information sheet and a screening questionnaire to check 
eligibility and given at least 24 hours to decide whether to participate. Informed consent was 
obtained on the day of the experiment.  Participants were paid £10 for their time. The 
experiment took 1 hour to complete. 
2.2. Measures  
Sociodemographics 
We asked participants to provide their age in years, gender, ethnicity, current qualification 
they were studying (undergraduate or postgraduate degree) and first language. 
Treatment Beliefs 
1. Pharmaceutical Schema and general Treatment Beliefs 
Beliefs about Medicines Questionnaire – General (BMQ-G) [20] 
The BMQ-G consists of 3 scales: a 4-item scale assessing beliefs about the benefit of 
medicines in general (General Benefit; e.g. ‘Medicines help many people to live better lives’), 
a 5-item scale assessing their capacity to cause harm (General Harm; e.g. ‘All medicines are 
poisons’) and a 3-item scale assessing their overuse by doctors (General Overuse; e.g. 
‘Doctors use too many medicines’). All items were scored on a 5-point Likert-type scale 
(1=strongly agree, 2=disagree, 3=uncertain, 4=agree, 5=strongly agree). A scale-adjusted 
mean score for each scale was computed by dividing the mean scale score by the number of 
items. All 4 scales have been validated [17] and had adequate reliability in the current 
sample (General Benefit α = 0.55, General Harm α = 0.64, General Overuse α = 0.67).  
Perceived Sensitivity to Medicines (PSM) [17] 
The PSM is a 5-item scale assessing beliefs about personal sensitivity to the effects of 
medicines (e.g. ‘My body is very sensitive to medicines’). All items were scored on a 5-point 
Likert-type scale (1=strongly agree, 2=disagree, 3=uncertain, 4=agree, 5=strongly agree). A 
scale-adjusted mean score for each scale was computed by dividing the mean scale score 
by the number of items. The PSM has been validated [17] and had adequate reliability in the 
current sample (α = 0.78). 
Complementary and Alternative Medicines Belief Inventory (CAMBI) [2] 
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The CAMBI measures Beliefs about Complementary and Alternative Medicine. It has four 5-
item subscales measuring beliefs about: Holistic Health (health and illness involve the whole 
person e.g. “Health is about harmonizing your body, mind and spirit”); Holistic Treatments 
(treatment should focus on the body’s healing mechanisms e.g. “It is important for 
treatments to boost my immune system”); Natural Treatments (natural treatments are safer 
than orthodox medicines) e.g. “Treatments should only use natural ingredients”; and 
Participation in Treatment (patients should be actively involved in their treatment ). Items 
were scored on a 7-point Likert-type scale (0=strongly disagree, 7=strongly agree). Scores 
for each item were summed to produce a total score for each scale. This questionnaire has 
shown good validity [2]. The Holistic Health, Holistic Treatment and Natural Treatment 
scales had adequate to good internal consistency in our sample (α = 0.59, 0.61, 0.49 
respectively). The Participation in Treatment scale had poor internal consistency (α = 0.28) 
and so was not used in the analysis.  
2. Specific beliefs about the placebo cream (Beliefs about Medicines Questionnaire – 
Specific Scale; BMQ-S) [20] 
The BMQ-Specific was used to assess perceptions of the ‘pain-relieving’ cream. It comprises 
two scales: a 5-item Necessity scale assessing perceptions of personal need for the cream 
and a 6-item Concerns scale assessing concerns about potential negative effects of the 
cream. The BMQ-S was developed for examining beliefs about medicines prescribed for 
those with ongoing health issues. As our sample were healthy individuals experiencing 
experimentally induced pain we modified each item to apply to this setting (see Table 1). 
Items were scored on 5-point Likert-type scales (where 1=strongly agree, 5=strongly agree). 
A scale-adjusted mean score for each scale was computed by dividing the mean scale score 
by the number of items. Both scales had good internal consistency in both conditions 
(Pharmaceutical Condition: Necessity α = 0.61, Concerns α = 0.71, Natural Condition: 
Necessity α = 0.68, Concerns α = 0.64). 
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3. Treatment preference 
Participants were asked to choose which cream they would use if they were suffering from 
muscle pain.  
Pain Catastrophizing Scale (PCS) [34] 
The PCS is a 13-item questionnaire measuring propensity to exaggerate the seriousness or 
threat value of pain. It can be divided into 3 subscales measuring Rumination (e.g. “I can’t 
stop thinking about how much it hurts”; PCS-Rumination), Magnification of Pain (e.g. “I worry 
that something serious may happen”; PCS-Magnification), and Feelings of Helplessness 
(e.g. “It’s awful and I feel that it overwhelms me”; PCS-Helplessness) during pain. 
Participants indicate the degree to which they have these thoughts and feelings using a 5 
point scale (0=not at all, 4=all the time). Totals for each subscale are calculated by adding 
scores from each item. This questionnaire has been validated [27] and had good internal 
consistency for all 3 subscales (PCS–Rumination α = 0.75, PCS–Magnification α = 0.85, 
PCS-Helplessness α = 0.59).  
Expectations of drug efficacy and Pain Intensity (VAS) 
Visual Analogue Scales (VAS) were used to measure expectations of drug efficacy (Efficacy 
Expectations: 0 = Not effective at all, 100 = Highly effective), and Expected Pain Intensity (0 
= Least possible pain, 100 = Worst possible pain).  
Patient Health Questionnaire – 9 (PHQ-9) [21] 
The PHQ-9 is a 9-item screening assessment for depression severity. Participants indicated 
how bothered they had been about 9 features of depression, over the past 2 weeks (e.g. 
“Little interest or pleasure in doing things”). Items were scored on a 4-point Likert-type scale 
(0=not at all, 1=several days, 2=more than half the days, 3=nearly every day). A total score 
was calculated by summing item scores. It has been validated in clinical and general 
populations [21; 23], and had good internal consistency (α = 0.87). 
State Trait Anxiety Inventory – Trait (STAI-T) [32] 
This 20-item questionnaire was used to measure Trait Anxiety. For each item, participants 
rated how they generally feel (e.g. “I feel nervous and restless”) using a 4-point scale 
(1=almost never, 4=almost always). A total score was calculated by adding scores from each 
item. It has shown good validity [32] and had good internal consistency (α = 0.75). 
Positive and Negative Affect Schedule - State (PANAS) [40] 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
 
State Affect was measured using the PANAS, which consists of two 10-item scales 
measuring Positive Affect and Negative Affect. Both scales showed good internal 
consistency for all 3 conditions (Pharmaceutical Condition: Positive Affect α = 0.91, Negative 
Affect α = 0.85, Natural Condition: Positive Affect α = 0.93, Negative Affect α = 0.83, No 
Placebo Condition: Positive Affect α = 0.93, Negative Affect α = 0.83). Participants indicated 
how they are feeling at that moment (e.g. “Interested”, “Scared”) using a 5-point scale 
(where 1= very slightly or not at all, to 5 = extremely). Scores for each scale were calculated 
by adding each item score.  
Pain Tolerance 
Pain Tolerance was measured by timing how long participants left their hand submerged in 
the water bath. Pain Tolerance was defined as the time from immersion to withdrawal of the 
hand from the water. 
Short-Form McGill Pain Questionnaire (SF-MPQ) [24] 
The SF-MPQ measures Pain Intensity using a visual analogue scale (VAS, 0 = Least 
possible pain, 100 = Worst possible pain), and Multidimensional Pain Intensity scale (MPQ) 
using 11 items assessing sensory pain and 4 items assessing affective pain. For each MPQ 
item, participants rated how much of that quality (e.g. sharp) their pain had from 0 =none to 
3 = severe. The scale showed good internal consistency for each condition (Pharmaceutical 
Condition α = 0.85, Natural Condition α = 0.84, No Placebo Condition α = 0.81). Total scores 
for each scale were calculated by adding the score from each item. Participants also 
completed the Present Pain Intensity measure (PPI) where they are asked to rate their 
overall pain intensity from 0 = no pain to 5 = excruciating. 
Side Effect Frequency 
Participants were provided with a list of 6 common side effects to pain medication  – Skin 
Irritation, Headache, Nausea, Dizziness, Fatigue, Hot flushes and were asked to report if 
they had experienced them or not. They were also provided with the option to note any other 
side effects they had experienced. 
Manipulation Checks 
Participants were asked to state what they thought the aim of the study was. Finally using a 
VAS, they were asked whether they thought they had received a placebo or an active 
medication for each condition (where 0=placebo and 100=active medication).  
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2.3. Conditions  
In the Natural and Pharmaceutical Conditions participant were presented with patient 
information leaflets describing each ‘treatment’ (see Figure 2 and 3). Side effect information 
was not provided to participants in the Natural and Pharmaceutical Conditions. In the No 
Placebo Condition participants were provided with the following message: “The purpose of 
this condition is to compare normal pain severity/tolerance against the condition where you 
will receive a medicine to see how effective the drugs are in reducing pain”. 
 
 
Figure 2: Patient information leaflet for the Pharmaceutical Placebo. 
 
Figure 3: Patient information leaflet for the Natural Placebo. 
2.4 Cold pressor task 
The temperature of the water bath (Julabo F-12 Refrigerated Circulator) was set at 2ºC [5]. 
Participants were instructed to submerge their hand in the water up to their wrist for as long 
as possible (maximum 2 minutes). The experimenter remained out of view during this task to 
reduce any audience effects from influencing results. 
2.5. Filler task  
Between each condition, participants were asked to complete a ‘Magic Square’ task to keep 
them engaged while their hand re-acclimatised to normal temperature. The task involved a 
3x3 grid where they were required to place numbers from 1-9 in each square so that each 
row column and diagonal adds up to 15 [31]. Participants were told that this task was to test 
their cognitive abilities after experiencing pain and to complete it within 5 minutes. 
2.6. Procedure  
Participants first completed the Baseline Measures (Sociodemographics, BMQ-G, PSM, 
CAMBI, PHQ-9, STAI-T, and PCS). Then they were exposed to each condition in a 
randomized order. Hand order (dominant – non-dominant - dominant hand or vice versa) 
was also randomized. Randomisation was determined for each participant using an online 
randomiser (unblind, using www.randomizer.org) before participants came in for the 
experiment and they were not told the order of conditions. In each condition, participants 
read the Condition-Specific Message, then the completed the Condition-Specific Measures 
(BMQ-S, PANAS and Expectations) and the cold pressor task. Pain Tolerance was 
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measured during each cold pressor task. Immediately after the task participants completed 
the Post-Cold Pressor Measures (SF-MPQ, Side Effects). Between each condition 
participants completed the filler task. 
Once all conditions had been completed, participants completed the Manipulation Checks. 
Finally, participants were fully debriefed (see Figure 4). 
 
Figure 4: Overview of procedures. BMQ-G = Belief about Medicines Questionnaire – 
General, PSM = Perceived Sensitivity to Medicines, CAMBI – Complementary and 
Alternative Medicines Belief Inventory, PHQ-9 = Patients Health Questionnaire – 9, STAI-T = 
State Trait Anxiety Inventory – Trait, Pain Catastrophizing Scale, PANAS, Positive and 
Negative Affect Schedule, BMQ-S = Beliefs about Medicines Questionnaire – Specific, SF-
MPQ = Short Form McGill Pain Questionnaire. 
2.7. Statistical analysis 
Analyses were used to address the following questions/hypotheses: 
Descriptive statistics 
Baseline measure scores were dichotomized at either the scale mid-point or at the median 
score for descriptive purposes 
Was the placebo cream convincing? 
Paired t-tests were performed to determine if there were significant differences in Expected 
Efficacy, Expected Pain Intensity, Necessity and Concerns, Pain Intensity (VAS, MPQ, PPI), 
and Pain Tolerance across conditions. Scores for the BMQ-S subscales were dichotomized 
at the scale mid-point to describe participants as high or low on each subscale. Scores for 
Necessity and Concerns in the Natural Condition were subtracted from the Pharmaceutical 
Condition to determine whether participants formed different perceptions about the placebo 
cream in each condition. 
Did we observe a placebo effect? 
Repeated-measures ANOVA was used to determine whether a significant placebo effect 
was observed in response to the Pharmaceutical and Natural Placebo (MPQ, VAS and OPI 
Pain Intensity, and Pain Tolerance). 
Hypothesis 1: Variation in placebo responses in both conditions will be predicted by the 
participant’s Necessity beliefs. 
The placebo effect for Pain Intensity (MPQ, VAS and PPI Placebo Effect) and Tolerance 
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(Tolerance Placebo Effect) were calculated by subtracting scores obtained in the 
Pharmaceutical and Natural Conditions from the No Placebo Condition. We employed 
multiple linear regression to determine whether Necessity beliefs predicted variations in 
placebo analgesia in each condition. We used the placebo effect derived from the MPQ 
scale (MPQ Placebo Effect) as our primary outcome measure for Pain Intensity as it is a 
multidimensional measure of pain. Secondary outcome measures included VAS, OPI and 
Tolerance Placebo Effect. In addition to this, we also examined the effect of other specific 
treatment beliefs (specific concerns), participants’ Pharmaceutical Schemas (General 
Benefit, Harm and Overuse, PSM), Beliefs about CAM (CAMBI: Natural Treatments, Holistic 
Treatments, Holistic Health) and Expectations (Efficacy Expectations and Expected Pain 
Intensity) on placebo analgesia in each condition. 
Hypothesis 2: High pain catastrophizing will be associated with stronger Necessity beliefs 
and a larger placebo effect. 
We then tested the effects of Pain Catastrophizing on the placebo effect for each condition 
using multiple linear regression. A Sobel test determined whether any effect of beliefs about 
the impending pain (Pain Catastrophizing) on the placebo effect was mediated by Necessity. 
Finally we included significant predictors in a regression model to determine the overall 
variance of the placebo effect by these variables.  
Hypothesis 3: Specific Necessity will be differentially influenced by general pharmaceutical 
schema and general beliefs about complimentary medicine. 
Pearson’s correlations were conducted to examine relationships between general beliefs 
about medicines, PSM, Specific Beliefs about the placebo and Beliefs about CAM. A 
binomial test was used to determine whether there was a significant preference for either the 
Natural or Pharmaceutical Placebo within our sample. Independent t-tests were conducted 
to determine significant difference in treatment beliefs, beliefs about CAM and Pain Intensity 
in response to each placebo between those who preferred to use the Natural vs. 
Pharmaceutical Placebo. Analyses were conducted using IBM SPSS Statistics v21. 
 
3. Results 
3.1. Sample characteristics 
Of 236 individuals who expressed interest, 21 did not meet the inclusion criteria. Of the 215 
who agreed to take part after screening, 47 did not attend their appointment and 168 
attended and completed the experiment. The mean age of these participants was 25.69 
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years with the majority being female (63.70%). Just over a third of participants were currently 
studying an undergraduate degree with the rest studying for a postgraduate degree. Most 
participants spoke English as their first language (see Table 2). 
 
3.2. Baseline Measures 
Pharmaceutical schema and general beliefs about medicines 
Most participants expressed positive views about pharmaceutical medicines. All but one 
participant (99.40%) had high General Benefit beliefs, scoring above the scale mid-point 
(mean = 3.98 SD= 0.45). The majority of our sample viewed medicines as generally safe 
(Low General Harm 81.50%, mean = 2.24 SD = 0.59) and had low PSM (93.50%, mean = 
2.05 SD = 0.58), scoring below the scale mid-point. However, two thirds of our sample 
believed that medicines are over prescribed by doctors, scoring above the scale mid-point 
(66.70%, mean = 3.06 SD = 0.69). Mean scores for the CAMBI – Natural Treatment, Holistic 
Treatment and Holistic Health scales were 17.45 (SD = 4.51), 20.65 (SD = 3.86) and 15.38 
(SD = 3.81), respectively. These scores were around the scale midpoint suggesting 
participants were ambivalent to whether medication should be natural, utilize the body’s own 
mechanisms, and focus on the body “as a whole”.  
State/Trait Psychological Variables 
A median Depression score of 3 (IQR = 6) was observed with 18.5% of our sample scoring 
above the criteria for depression severe enough to warrant medical intervention. Mean 
scores for PCS – Rumination, Magnification and Helplessness were 5.24 (SD = 3.90), 2.43 
(SD = 1.99) and 4.90 (SD = 3.98) suggesting participants generally were low pain 
catastrophizing tendencies (scoring below the scale mid-point). Finally a mean Trait Anxiety 
score of 43.18 (SD = 6.49) was observed suggesting moderate levels of Trait Anxiety within 
our sample (see Table 3). 
3.3. Was the placebo cream convincing? Manipulation check and side effect reports 
We conducted paired t-tests to determine whether participants tended to have different 
beliefs and expectations about the Natural and Pharmaceutical Placebos. Regardless of 
whether the treatment was described as Pharmaceutical or Natural, Mean Necessity beliefs 
in each treatment condition were above the scale mid-point, indicating that most participants 
felt that they needed the treatment, while Concerns were low, with a mean below the scale 
mid-point. Necessity beliefs were significantly greater in the Pharmaceutical Condition 
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compared to the Natural Condition (mean difference score= 0.19 SD = 0.54) (see Table 4). 
Concerns about its adverse effects were also typically higher for the Pharmaceutical cream 
than the Natural cream (mean difference score 0.20, SD = 0.50). However, there was 
variation in how participants perceived the placebos, with some participants having higher 
Concerns and higher perceived need for the Natural cream (see Figure 5).  
 
Figure 5: Frequency distributions for Necessity (left) and Concerns (right) difference scores. 
Participants expected less pain from the cold pressor task when they were given the cream 
(Pharmaceutical and Natural Conditions) than when they were not given a cream (No 
Placebo Condition). There was not a significant difference in expected pain between the 
Natural and Pharmaceutical Conditions. Overall, participants expected the Pharmaceutical 
Placebo to be more effective than the Natural Placebo (see Table 4). 
 
Most of our participants believed that the cream was, or could be an active drug; only 6 of 
our 168 participants thought the cream was definitely a placebo (Pharmaceutical Condition: 
mean = 51.90, SD = 23.77, Natural Condition: mean = 51.39, SD = 25.21). Furthermore, at 
least one side effect was reported by 38.2% of participants in the Pharmaceutical Condition 
and 32.3% of participants in the Natural Condition. Skin irritation was the most commonly 
endorsed side effect in both conditions (Pharmaceutical Condition: 16.1%, Natural Condition: 
13.7%) and headache was the least common (0.6% in both conditions).  
 
3.4. Did we observe placebo effects? 
Pain Intensity (MPQ, VAS and OPI) and Pain Tolerance scores for each condition were 
entered into a repeated-measures ANOVA to determine whether a significant placebo effect 
was observed.  
There was a significant group effect of condition on Pain Intensity (VAS: F (2, 166) = 7.71, 
p<0.01, MPQ: F (2, 166) = 3.74, p < 0.05) and Pain Tolerance (F (2, 166) = 5.94, p<0.01). 
No significant group effect was observed for OPI Pain Intensity (F (2, 166) = 2.23, p = 0.11).  
Post-hoc analyses revealed a significant placebo effect was observed in both the 
Pharmaceutical and Natural Conditions for VAS Pain Intensity. Similarly, participants were 
able to tolerate the pain significantly longer in both the placebo conditions compared to the 
No Placebo Condition. There was no significant difference in Pain Tolerance or VAS Pain 
Intensity between the Natural and Pharmaceutical Conditions (see Table 5). 
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Participants reported lower MPQ Pain Intensity when they used the Natural Placebo than 
when they used No Placebo, but did not when they used the Pharmaceutical Placebo. No 
significant differences in MPQ Pain Intensity were observed between the Pharmaceutical 
Condition and the No Placebo Condition or Natural Condition, respectively (see Table 5). 
3.5 Hypothesis testing 
Sociodemographics had no significant effect on the MPQ, VAS, OPI or Tolerance Placebo 
Effect and were therefore not included in subsequent analyses. 
Hypothesis 1: Variation in placebo responses in both conditions will be predicted by 
the participant’s Necessity beliefs. 
Multiple linear regression showed that the MPQ Placebo Effect was significantly positively 
associated with Specific Necessity beliefs for each treatment (Pharmaceutical: F change 
(2,168) = 10.75, p < 0.01 vs Natural: F change (2,168) = 6.37, p < 0.05), confirming 
Hypothesis 1. Specific Necessity beliefs explained 6.1% (Pharmaceutical) and 6.9% 
(Natural) of the variation in MPQ Placebo Effect. Participants response increased by 0.25 
and 0.19 units per unit increase in Necessity for the Pharmaceutical and Natural Conditions, 
respectively (see Table 6). 
Scores on the Perceived Sensitivity to Medicines Scale (PSM – an aspect of pharmaceutical 
schema), explained 2.5% of the MPQ Placebo Effect in the Pharmaceutical Condition (F 
change (2, 168) = 4.17, p < 0.05) but not in the Natural Condition (p> 0.05). The MPQ 
Placebo Effect increased by 0.14 units per unit increase in PSM in the Pharmaceutical 
Condition (see Table 6). No other treatment beliefs were significant predictors of the MPQ 
Placebo effect or secondary outcome measures in response to the Natural and 
Pharmaceutical Placebos (all p > 0.05). 
The effect of Necessity remained significant when Efficacy Expectations were included in the 
model (Pharmaceutical: F change (2,168) = 8.16, p < 0.01 Natural: F change (2,168) = 5.36, 
p < 0.05) Conditions (see Table 6 and Figure 6). Sociodemographics, Trait Anxiety, 
Depression and Affect also had no significant effect on this relationship (all p > 0.05).  
 
Figure 6: Relationship between the MPQ Placebo Effect and (a) Necessity and (b) 
Necessity while controlling for Efficacy Expectations (95% CI). 
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Hypothesis 2: High pain catastrophizing will be associated with stronger Necessity 
beliefs and a larger placebo effect. 
Responses to the pharmaceutical and Natural Placebos were predicted by two of the three 
components of pain catastrophizing: Feelings of Helplessness (Pharmaceutical: F change 
(2,168) = 18.93, p < 0.05: 3% variance explained, Natural: F change (2,168) = 18.93, p < 
0.05, 2% variance explained) and Magnification of Pain (Pharmaceutical:  F change (2,168) 
= 4.05, p < 0.05, 1.5% variance explained, Natural: F change (2,168) = 6.23, p < 0.05, 2.6% 
variance explained, see Table 6). Rumination was not significantly related to MPQ Pain 
Intensity responses in either placebo condition (all p > 0.05). Components of pain 
catastrophizing were not significantly associated with secondary outcome measures in 
response to the Natural and Pharmaceutical Placebos (all p > 0.05). 
As we found that personal need for the placebo cream and two components of pain 
catastrophizing significantly predicted the MPQ Placebo Effect, we investigated whether 
Necessity beliefs mediated the relationship between feelings of Helplessness and 
Magnification of pain, and the MPQ Placebo Effect. Personal need for the placebo partially 
mediated the effect of Feelings of Helplessness on the MPQ Placebo Effect (Pharmaceutical 
Condition = Sobel test statistic: 2.26, p<0.05, Natural Condition = Sobel test statistic: 1.99, 
p<0.05). Personal need for the placebo did not significantly mediate the effect of 
Magnification of Pain on the MPQ Placebo Effect (p>0.05, see Figure 7 for statistics). 
 
Figure 7: Necessity significantly partially mediated the effect of Helplessness on the MPQ 
Placebo Effect but not Magnification of pain. Figure shows regression coefficients. *p<0.05, 
**p<0.01. PCS = Pain Catastrophizing. 
Hypothesis 3: Specific Necessity will be differentially influenced by general 
pharmaceutical schema and general beliefs about complimentary medicine.  
We used Pearson’s correlations to test for relationships between Specific Beliefs about the 
placebo, pharmaceutical schemas (general beliefs about medicines and PSM) and Beliefs 
about CAM (CAMBI). Pharmaceutical schemas influenced evaluations of the specific 
placebo treatments. Individuals were more likely to endorse the Necessity of the 
Pharmaceutical Placebo treatment if they believed that pharmaceutical medicines were 
intrinsically beneficial. Participants were more likely to reported greater Concerns about 
potential adverse effects of both the Pharmaceutical and Natural Placebos if they believed 
that pharmaceuticals are intrinsically harmful (General-Harm) or believed they were 
particularly sensitive to the effects of medicines (PSM). Perceived need for the Natural 
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Placebo was not influenced by participants’ Pharmaceutical Schema.  Finally, those who had 
more positive Beliefs about CAM were more likely to endorse the Necessity of the Natural 
Placebo and report greater Concerns about the Pharmaceutical Placebo (see Figure 8 for 
statistics).  
 
Figure 8:  Significant relationships between Specific Beliefs about the Placebo, 
Pharmaceutical Schemas, CAMBI and Specific Beliefs about the pharmaceutical and Natural 
Placebos. PSM – Perceived Sensitivity to Medicines, CAMBI – Complementary and 
Alternative Medicines Beliefs Inventory. * P<0.05, ** P<0.01. 
Hypothesis 4: Negative pharmaceutical schema will be associated with more positive 
beliefs about complementary and natural remedies and preferences for this type of 
treatment. 
A binomial test was used to determine whether there was a significant preference either the 
Natural or Pharmaceutical Placebo within our sample. There was an overall but non-
significant preference for the Natural Placebo (54.49%, p > 0.05). Independent t-tests were 
conducted to determine whether there were significant differences in Treatment Beliefs and 
Beliefs about CAM between those who would prefer to use the Natural Placebo and those 
who would prefer to use the Pharmaceutical Placebo in a real health situation. Those who 
preferred to use the Natural Placebo tended to believe that pharmaceuticals were less 
beneficial, more intrinsically harmful and overused and had higher PSM than those who 
preferred to use the Pharmaceutical Placebo. Those who preferred to use the Natural 
Placebo also had significantly higher Concerns about the Pharmaceutical Placebo and more 
positive beliefs about CAM than those who preferred to use the Pharmaceutical Placebo 
(see Table 7 for statistics).  
Independent t-tests were conducted to determine whether Pain Intensity in response to each 
placebo was different for those who preferred the Natural vs. Pharmaceutical Placebo. We 
found that Pain Intensity in response to the Pharmaceutical Placebo was significantly lower 
in participants who preferred the Pharmaceutical over the Natural Placebo than vice versa 
(Pharmaceutical: mean reduction = 0.99, SD = 0.27, Natural: mean reduction = 0.01, SD = 
0.42, t(167) = 1.93, p < 0.05). No significant difference in Pain Intensity was found in 
response to the Natural Placebo in those who preferred Natural vs Pharmaceutical Placebo 
(p >0.05). 
4. Discussion 
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This study is the first to show a causal relationship between treatment beliefs and the 
placebo effect. In a randomised, controlled experiment with cross-over design, we 
investigated whether pain responses to the cold-pressor task were reduced by two types of 
sham analgesics (deceptive placebos) described as ‘natural’ vs pharmaceutical and whether 
responses were predicated by treatment beliefs.  
Placebo responses predicted by treatment beliefs 
We assessed two categories of treatments belief: general beliefs about the particular types 
of (sham) treatment (natural vs pharmaceutical) and specific beliefs about the (sham) 
treatment allocated in condition. For the latter, we focussed on treatment Necessity, as an 
indicator of the value that the participant placed on each particular treatment  
Both placebos significantly improved pain tolerance. A reduction in pain intensity was 
observed in both the pharmaceutical and natural conditions but was only was statistically 
significant for natural. Placebo effects were predicated by specific and general treatment 
beliefs. Specific Necessity beliefs predicted placebo responses (pain intensity and tolerance) 
in both natural and pharmaceutical conditions. Placebo effects were also directly, and 
specifically, influenced by beliefs about personal sensitivity to pharmaceutical medicines. 
Those who believed themselves to be sensitive to pharmaceuticals reported a greater 
reduction in pain intensity in the pharmaceutical condition but not in the natural condition.  
Observed effects were consistent with theoretical predictions 
Our findings were consistent with theoretical predictions (see Figure 1). Participants’ beliefs 
about their personal need for each type of placebo were influenced by more general beliefs 
about pharmaceuticals and CAM as classes of treatment as predicted by our theoretical 
model [14]. Participants were more likely to endorse the Necessity of the pharmaceutical 
placebo, but not the natural placebo, if they believed that pharmaceutical medicines are 
intrinsically beneficial. Necessity beliefs for the Natural Placebo were influenced by general 
beliefs about CAM but not by pharmaceutical schema. Those who believed that 
pharmaceuticals are intrinsically harmful or perceived themselves to sensitive to medicines 
had stronger concerns about both the pharmaceutical and natural placebos.  
Preference for the Natural Placebo was associated with more negative pharmaceutical 
schema, greater concerns about the Pharmaceutical Placebo and more positive beliefs 
about CAM. These findings are consistent with previous studies [2; 9] and theoretical 
predictions that preferences for specific treatments are influenced by more general 
perceptions of classes of treatment, which vary between individuals[14; 20]  
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Also in accordance with theoretical predictions (Figure 1), representations of the problem 
(feelings of helplessness) influenced representations of the solution (treatment Necessity 
beliefs) which in turn influenced the placebo effect. Furthermore, we found that the effects of 
feelings of helplessness on the placebo responses were mediated by Necessity beliefs.  
Participants expected the pharmaceutical placebo to be more effective yet the placebos did 
not differ in their effect on pain perception. However, participants also had more concerns 
about adverse effects in the pharmaceutical than in the natural condition. This combination 
of results suggests an interesting constellation of challenges for both types of ‘intervention’.  
Pharmaceuticals seem to benefit from larger expectations of efficacy which could potentially 
boost their therapeutic outcome.  But this desired effect may be counteracted by heightened 
concern about adverse effects. This is consistent with observations that pharmaceuticals are 
often perceived as a ’double-edged sword’ where therapeutic efficacy goes hand in hand 
with toxicity[13; 14]. This observation might also help explain our, apparently anomalous, 
finding that high Necessity beliefs for the pharmaceutical placebo were predicted by beliefs 
that pharmaceuticals are intrinsically beneficial but also by beliefs that they are intrinsically 
harmful.  
Strategies, to improve the outcome of pharmaceuticals might therefore want to target 
concerns about potential side effects as well as enhancing prior expectations because highly 
efficacious medicines may be perceived to be intrinsically more toxic, as their ‘power’ has 
dual effect: benefit and harm. This idea is supported by the observation that treatment 
Necessity beliefs and concerns are sometimes positively correlated in clinical samples [3; 
15; 18]. The issue seems to be reversed for natural treatments. There is less worry about 
side effects (which could hinder the therapeutic effect), but a low expectancy level might 
undermine a positive treatment experience [9]. 
Beyond expectations 
Our findings suggest that placebo effects are susceptible to more complex and diverse 
beliefs about a treatment than expectations of efficacy alone. In contrast to previous studies 
[10; 11; 28; 30; 38], we did not find a significant effect of expectations on the placebo effect. 
This may be a consequence of our experimental design. Usually expectation-focused 
studies involve directly inducing different expectations of symptom severity after placebo 
administration [30; 37]. In our study we told participants that both treatments were “highly 
effective” and participants may therefore have had high expectations of both placebos. 
Efficacy expectations are likely to contribute to perceptions of treatment Necessity [14; 19]. 
For example, a previous study found that 25% of the variance in the perceived need of anti-
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retroviral medication was due to efficacy expectations. However, Necessity beliefs are not 
synonymous with efficacy expectations [14]. We might perceive the need for a treatment that 
we believe will have only minimal effects because we perceive a personal value in achieving 
that effect or if it is the only treatment option available. Likewise, we may perceive a 
treatment to be effective, but, at the same time, to be of low personal value because we are 
unconvinced of our need for it. In this respect Necessity beliefs can be considered as an 
indicator of the value that the individual places on the specific treatment [14].  
Limitations 
Our study had several limitations. Our student sample was highly educated, younger, and 
possibly healthier than the general population, limiting the generalisability of our findings. 
There is no definitive protocol for the cold pressor paradigm leading to variations in 
equipment and water temperature that may influence results across studies. Furthermore, 
habituation, audience, and demand effects are all known to influence pain and tolerance [12; 
25; 39; 42; 43]. We minimised these effects by conducting the experiment in a private room, 
keeping the experimenter, information and instructions to participants constant, and keeping 
the temperature of our water bath constant within +0.03ºC. We minimised the effect of 
habituation on our results by randomising both condition order and hand order. Although we 
did observe significant order effects for the natural condition but not in the pharmaceutical 
condition, our results were as predicted in both conditions. We suspect that this effect 
represents some degree of habituation; however, this did not influence our results. We also 
allowed time between conditions for participants’ hands to reacclimatise to room 
temperature.  
We did not observe a significant placebo effect in response to every pain measure. For 
example, we found no significant MPQ Placebo Effect in the Pharmaceutical Condition but 
did in the Natural Condition. However, our analyses were still able to predict which 
participants would report a larger placebo effect based on their beliefs about each placebo. 
We conducted a manipulation check at the end of our experiment to ensure that our results 
were not simply due to demand effects. The majority of our sample believed that both pain 
relieving creams were active medications. A third of our sample reported a side effect which 
supports that the placebo cream was convincing as a drug. The study had several strengths. 
We recruited a large sample size and employed a within subject design, thus maximising 
statistical power and reducing error variance associated with individual differences. Pain 
Intensity scores were similar to the magnitude of pain in a number of untreated clinical pain 
conditions [8; 29; 41]. Differences between Pain Intensity and Tolerance in the No Placebo 
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Condition and in both Placebo Conditions were also similar to previous studies investigating 
the placebo effect using the cold pressor task [6; 28; 33].  
Conclusion 
Despite its limitations, this study demonstrated that placebo effects were influenced by 
specific and general treatment beliefs in a way that was consistent with theory. Participants 
differed in their background beliefs about pharmaceutical and natural treatments and 
perceptions self in relation to medicines (personal sensitivity to medicines). Pharmaceutical 
schema influenced their evaluation of specific pharmaceutical and natural (sham) treatments 
and their beliefs in the necessity of the treatment for reducing pain, which in turn, influenced 
pain responses. Our findings suggest that beliefs about treatment may offer an additional 
approach for studying placebo effects. Further studies are now justified to explore these 
issues in more detail to assess further the value of treatment beliefs in understanding 
placebo effects.  
Our findings might also stimulate research in clinical samples A proportion of the outcome of 
active treatments is explained by non-specific effects placebo effects exist when taking 
active medications [4]. Furthermore, there is evidence that treatment beliefs influence side 
effect reporting [1; 17; 26].  The treatment beliefs we studied have previously been shown to 
influence adherence to medicines in numerous studies [15]. It may be that interventions that 
to support adherence by influencing these beliefs might also have a direct effect on 
treatment outcome.   
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Table 1: Modified items of the BMQ-S scales 
Necessity  
 
Concerns 
This cream is necessary to reduce my pain   Using this cream worries me 
I would experience more severe pain without this cream  I am concerned about the long-term effects of this cream 
Using this cream makes me less anxious about the pain in 
this study 
 How this cream works is a mystery to me 
This pain relieving cream will protect me from feeling pain 
 I am concerned that this cream won’t work  
I am concerned that this cream might cause a side effect  
 
 I am concerned this cream will affect my sense of touch in 
my hand 
  It would worry me to feel as though I depended on this 
cream to tolerate the pain 
  
Note: BMQ-S = Beliefs about Medicines Questionnaire - Specific 
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Table 2: Demographics 
  Mean (SD) 
Age (years) 25.69 (8.40) 
  n (%) 
Female 107 (63.70%) 
Currently studying: 
    Undergraduate degree 59 (35.10%) 
    Postgraduate degree 93 (64.90%) 
Ethnicity 
   White British/American/European 92 (54.80%) 
   Other 75 (45.20%) 
First Language 
   English 100 (59.52%) 
   Other  64 (40.47%) 
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Table 3: Baseline measures 
  
  
Mean (SD) 
General Benefit 3.98 (0.45) 
General Harm 2.24 (0.59) 
General Overuse 3.06 (0.69) 
PSM 2.05 (0.58) 
CAMBI - Natural Treatment 17.45 (4.51) 
CAMBI - Holistic Treatment 20.65 (3.86) 
CAMBI - Holistic Health 15.38 (3.81) 
Trait Anxiety 43.18 (6.49) 
PCS - Rumination  5.24 (3.90) 
PCS - Magnification 2.43 (1.99) 
PCS - Helplessness 4.90 (3.98) 
 Median (IQR) 
Depression 3.00 (6.00) 
Note: PSM – Perceived Sensitivity to Medicines Scale, CAMBI – Complementary and 
Alternative Medicines Belief Inventory, PCS – Pain Catastrophizing Scale 
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Table 4: Comparison of Specific Beliefs, Expected Pain Intensity and Expected Efficacy across conditions  
  Condition Mean (SD)   
No Placebo Pharmaceutical Natural p 
Necessity -- 3.35 (0.57) 3.16 (0.6) <0.001 
Concerns -- 2.64 (0.62) 2.44 (0.55) <0.001 
Expected Efficacy -- 64.82 (16.60) 57.88 (16.60) <0.01 
Expected Pain Intensity 67.08 (21.41) 47.07 (18.21) 50.21 (20.54) <0.001
a,b
 
Note: p values relate to paired t-tests. a = No Placebo – Pharmaceutical Condition, b = No Placebo – Natural Condition. 
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Table 5: Comparison of Pain Intensity and Pain Tolerance across conditions  
 Condition Mean (SD) 
p No Placebo Pharmaceutical  Natural  
Pain Intensity: 
MPQ 14.23 (8.32) 13.61 (7.73) 12.97 (7.51) <0.05
b
 
VAS 69.79 (18.68) 65.09 (18.21) 63.52 (19.68) <0.05
a
, <0.001b 
PPI 3.75 (0.96) 3.64 (0.84) 3.56 (0.89) <0.01
b
 
 
    
Pain Tolerance (seconds) 55.07 (44.32) 61.63 (43.73) 63.63 (43.09) <0.05
a
, <0.05b 
Note: VAS = Visual Analogue Scale, MPQ = McGill Pain Questionnaire, PPI = Present Pain Intensity. p values refer to 
the results of repeated-measures ANOVA post-hoc test (Bonferroni). Statistical comparisons - a = No Placebo - 
Pharmaceutical, b = No Placebo – Natural, c = Pharmaceutical - Natural 
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Table 6: The effect of a) Necessity b) Necessity while controlling for Efficacy Expectations 
c) PSM and d) Magnification of Pain and feelings of Helplessness on the MPQ Placebo 
Effect. 
Model Condition 
Pharmaceutical Natural 
B [95% CI] p B [95% CI] p 
a)     
Baseline: 
Constant 0.91 [0.67, 1.14] <0.001 0.59 [0.36, 0.81] <0.001 
Condition order 0.01 [ -0.01, 0.01] >0.05 0.01 [0, 0.01] <0.05 
Model 1: Baseline plus -  
Necessity 0.22 [0.09, 0.35] <0.01 0.16 [0.04, 0.28] <0.05 
     
b)     
Baseline:     
Constant 0.71 [0.37, 1.05] <0.001 0.50 [0.22, 0.78] <0.01 
Condition order 0.01 [-0.01, 0.01] >0.05 0.01 [0, 0.01] <0.05 
Efficacy Expectation 0.01 [-0.01, 0.01] >0.05 0.01 [-0.01, 0.01] >0.05 
Model 1: Baseline plus -      
Necessity 0.21 [0.06, 0.35] <0.01 0.16 [0.02, 0.29] <0.05 
     
c)      
Baseline:     
Constant 0.91 [7.60, 0.01] <0.001 - - 
Condition order 0.01 [0.05, 0.96] >0.05 - - 
Model 1: Baseline plus -      
PSM 0.14 [2.04,0.43] <0.05 - - 
     
d)     
Baseline:     
Constant 0.91 [0.67, 1.14] <0.001 0.59 [0.36, 0.81] <0.001 
Condition order 0.01 [ -0.01, 0.01] >0.05 0.01 [0, 0.01] <0.05 
Model 1: Baseline plus-     
PCS: Magnification 0.04 [0.01, 0.08] <0.05 0.05 [0.01, 0.09] <0.05 
Model 2: Baseline plus-     
PCS: Helplessness 0.03 [0.1, 0.05] <0.01 0.02 [0.01, 0.04] <0.05 
Note: MPQ = McGill Pain Questionnaire, PCS = Pain Catastrophizing Scale, PSM, 
Perceived Sensitivity to Medicines 
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Table 7: Comparison of Treatment Beliefs and beliefs about CAM between those who preferred to use the Pharmaceutical 
vs. Natural Placebo.  
 
 Preference for:  
(Mean (SD) p 
Pharmaceutical Placebo Natural  Placebo   
General Benefit 4.08 (0.39) 3.90 (0.48) < 0.01 
General Harm 2.08 (0.58) 2.54 (0.56) <0.001 
General Overuse 2.97 (0.70) 3.38 (0.71) <0.001 
PSM 1.89 (0.53) 2.18 (0.59) <0.01 
Pharmaceutical Placebo : Necessity 3.41 (0.53) 3.30 (0.65) >0.05 
Pharmaceutical Placebo : Concerns  2.45 (0.53) 2.81 (0.61) <0.001 
Natural Placebo: Necessity 3.12 (0.59) 3.19 (0.61) >0.05 
Natural Placebo: Concerns 2.37 (0.51) 2.50 (0.57) >0.05 
CAMBI: Holistic Health 14.50 (3.70) 16.18 (3.76) <0.01 
CAMBI: Holistic Treatment 19.70 (3.76) 21.45 (3.78) <0.01 
CAMBI: Natural Treatment 15.73 (4.11) 18.91 (4.34) <0.001 
Note: PSM = Perceived Sensitivity to Medicines, CAMBI = Complementary and Alternative Medicines Belief Inventory 
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Highlights 
Treatment beliefs offer an additional approach to understanding placebo analgesia 
Variation in placebo analgesia was predicted by pre-treatment necessity beliefs 
Treatment necessity beliefs were informed by general treatment beliefs and beliefs about the 
pain 
Perceived sensitivity to the effects of medicines was associated with larger placebo 
analgesia 
